

Wellnex Life Limited (ASX:WNX)

Update on IP Licensing

Wellnex Life Limited (ASX) ("Wellnex Life" or the "Company"), is pleased to provide a further update on the announcement released on 15 August 2024 in relation to Haleon placing its first purchase order (PO) for the UK market (Announcement).

Wellnex Life considers the Announcement to be material due to the significance of the expansion of the arrangement with Haleon to the large UK market, which the Company at all times has kept shareholders informed of the progress. Wellnex announced on 29 June 2023 the agreement to expand into the UK market and provided a further update on 15 February 2024 on Haleon obtaining regulatory approval to commence sales in the UK.

Wellnex Life since 1 July 2024 has received purchase orders from various customers of \$3.28 million, that is additional to the IP invoiced sales in July 2024 of \$0.75 million (Total: \$4.03 million).

The purchase orders received to date and the invoiced sales in July amounts to 95% of the total revenue for the IP Licensing part of the business in FY24 (FY24: \$4.27 million).

The growth on IP licensing and the continued growth of our brands has resulted in a strong start to the business for FY25.

This ASX announcement has been authorised by the Board of Wellnex Life Limited (ASX:WNX).

For further information, please contact:

Wellnex Life Limited (ASX:WNX)

George Karafotias

Chief Executive Officer

P: +61 3 8399 9419

E: george.k@wellnexlife.com.au

About Wellnex Life

Wellnex Life Limited (ASX: WNX) is a consumer healthcare business with a track record for developing, licensing, and marketing registered products and brands to customers in the growing healthcare market segment. Since listing in 2021, Wellnex Life has successfully launched a host of brands and products now ranged in major retailers in the healthcare market space, pharmacies and supermarkets included. Its distribution arrangements have seen Wellnex Life secure significant licensing arrangements with major pharmaceutical companies in Australia and globally that have given the company's registered products a distribution channel with a steadily increasing global geographic footprint.



Wellnex Life has more recently acquired leading Australian topical pain relief brand Pain Away. Its addition to Wellnex Life's product offering both compliments and accelerates the potential growth of the company's business operations. This transformational acquisition gives added impetus to Wellnex Life's financial growth and scale and reinforces its place as a major and respected participant in the growing healthcare market, both in Australia and overseas.

To learn more, please visit: www.wellnexlife.com.au/